• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Episode 16- Exploring the Benefits and Limitations of Available Agents

Video

During this segment, the panelists discuss how new agents have affected the expectations of physicians and patients in terms of overall outcomes. Unfortunately, they conclude that there is some disparity between the expectations and the reality.

Yehuda Handelsman, MD, FACP, FACE, FNLA, explains that our country has not achieved developing a multi-target agent. While certain drugs control certain events, they often lead to other events. Additionally, while treatment with agents such as glucagon-like peptide-1 is presented as a terrific treatment option, there is still a lack in data that demonstrates that it does in fact reduce cardiovascular disease.

Kenneth L. Schaecher, MD, FACP, CPC, agrees with Dr Handelsman but does feel that a benefit of the wide range of available agents has allowed professionals to treat patients with flexibility. Rather than treating a patient off of a specific protocol, this allows patients to be treated with a more personalized therapy concept.


Related Videos
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
James Robinson, PhD, MPH, University of California, Berkeley
James Robinson, PhD, MPH, University of California, Berkeley
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski, OT, MBA
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Carrie Kozlowski, OT, MBA
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.